ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO650

Effect of Roxadustat vs. Erythropoietin on Nutritional Status in Peritoneal Dialysis Patients: A Retrospective Study

Session Information

  • Home Dialysis - II
    November 04, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

  • 802 Dialysis: Home Dialysis and Peritoneal Dialysis


  • Luo, Xiao Jie, Shunde Hospital of Southern Medical University, Foshan, Guangzhou, China
  • Luo, Qimei, Shunde Hospital of Southern Medical University, Foshan, Guangzhou, China
  • Dou, Xianrui, Shunde Hospital of Southern Medical University, Foshan, Guangzhou, China

Roxadustat have been used to treat renal anemia in patients undergoing dialysis. The effect of roxadustat on nutritional status in peritoneal dialysis (PD) patients remains uncertain. We aimed to explore the effect of roxadustat on nutritional status, and explore the possible modifiers for the association in PD patients.


The current study included 136 PD patients with renal anemia. The primary efficacy endpoints included changes from baseline in nutrition-related parameters. Linear regression analysis was performed to analyze the correlation between use of roxadustat with Subjective Global Assessment (SGA) and Malnutrition-Inflammation Score (MIS). Logistics regression analysis was used to evaluate the risk factors for the indicators of MIS.


After a median treatment observation of 20.0 (25th-75th, 16.0–21.0) months, the changes from baseline in serum albumin, prealbumin, total cholesterol, high-density lipoprotein cholesterol, blood urea nitrogen and creatinine levels were not significantly different between two groups. Besides, the use of roxadustat was inversely associated with MIS (β, -0.263; 95% CI: -2.430, -0.096), and was positively associated with SGA (β, 0.440; 95% CI: 0.046, 0.834). Additionally, compared to patients in rHuEPO group, those with the use of roxadustat were associated with more dietary intake (OR, 0.405; 95% CI: 0.190-0.865) and fewer gastrointestinal symptoms (OR, 0.365; 95% CI: 0.164-0.809). The inverse association between the use of roxadustat with MIS was stronger in patients without RRF (P for interaction=0.019).


In short, this study found that the use of roxadustat was inversely associated with MIS and positively associated with SGA in PD patients.